Autolus Therapeutics (AUTL) Interest & Investment Income (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Interest & Investment Income for 9 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

• Quarterly Interest & Investment Income fell 56.67% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.0 million (down 41.34% YoY) and the FY2025 annual result came in at $19.0 million, down 41.34% from the prior year.
• Interest & Investment Income slipped to $3.2 million in Q4 2025 per AUTL's latest filing, from $4.4 million in the prior quarter.
• Over the last five years, Interest & Investment Income for AUTL reached as high as $9.7 million in Q2 2024 and fell as low as $28000.0 in Q3 2021.
• A 5-year average of $3.3 million and a median of $3.3 million in 2023 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2021 — Interest & Investment Income sank 91.37% — and 2023, when it jumped 12207.14%.
• Year by year, Interest & Investment Income stood at $149000.0 in 2021, then soared by 857.05% to $1.4 million in 2022, then surged by 111.08% to $3.0 million in 2023, then soared by 147.41% to $7.4 million in 2024, then slumped by 56.67% to $3.2 million in 2025.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $3.2 million, $4.4 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.